Read all the latest updates on our charity, clinical advances in melanoma treatment, patient stories, fundraising and events.
A personalised mRNA cancer vaccine has shown positive results in a large phase 3 clinical trial involving people with high-risk melanoma following surgery.
Clinical Advances
Read more
Melanoma Focus is delighted to announce the launch of the updated ano-uro-genital mucosal melanoma guidelines.
Charity News, Clinical Advances
Read more
MANIFEST: A UK Cancer Immunotherapy Response Research Platform
Charity News, Clinical Advances
Read more
Tebentafusp Now Approved Across the UK for Eligible Patients with Advanced Uveal Melanoma
Charity News, Clinical Advances
Read more
At the 2026 international American Society of Clinical Oncology (ASCO) conference, 5 year patient outcomes from an initial cancer vaccine study in people with high risk melanomas were promising.
Clinical Advances
Read more
Melanoma Focus is thrilled to share that neoadjuvant therapy has been approved by NHS England for macroscopic stage 3 melanoma patients with operable disease spread skin or mucosal melanomas. This follows approval of neoadjuvant treatment in Scotland, Wales and Northern Ireland.
Melanoma Focus have supported the clinical community to gain access of this treatment.
Charity News, Clinical Advances
Read more
The NICE Technology Appraisal Committee has published the draft guidance to currently NOT recommend lifileucel (TILs treatment) for previously treated unresectable or metastatic melanoma. This is not NICE's final guidance and the recommendations may change after the consultation which closes on 5pm on 22 January 2026.
Charity News, Clinical Advances
Read more
We invite clinicians, nurses, organisations, patients & patient representatives to comment on the skin immunotherapy side effect guidelines, supporting information & patient information.
Charity News, Clinical Advances
Read more
The University of Manchester is hosting its first Lab to Life: Innovations in Melanoma Research Conference UK, a conference focusing on translational research and treatment advances.
Clinical Advances
Read more
The Melanoma Margins trial (MelMarT-II), an international surgical melanoma trial has recruited its 3000th patient.
Charity News, Clinical Advances
Read more
Professor Sarah Danson presented the results of the DANTE trial at the international 2025 ASCO conference in Chicago. Melanoma Focus were so pleased to support this important UK trial.
Clinical Advances
Read more
Lifileucel is a new type of personalised immunotherapy treatment, that uses the patient’s own immune system (the body’s natural defence) to attack their melanoma. The treatment is called tumour-infiltrating lymphocyte (TIL) therapy.
Clinical Advances
Read more
